Abeona Therapeutics Inc. - Common Stock (ABEO)
Healthcare › Pharmaceutical Preparations
Price History
Feb 9, 2026 — Aug 16, 2026Investment Snapshot
- Trading 22% below Graham Number ($7.65) — significant margin of safety
- Piotroski F-Score 5/9 — moderate financial health
- Strong ROE of 51.9% with 1,141.0% net margin
- Revenue growing at 66% annually
Abeona Therapeutics Inc. - Common Stock (ABEO) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NASDAQ , with a market capitalisation of $342 million . Key value metrics: P/E ratio 5.2, P/B ratio 2.67, Piotroski F-Score 5 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Abeona Therapeutics Inc. - Common Stock — Fundamental Analysis Summary
Abeona Therapeutics Inc. - Common Stock (ABEO) is trading 22% below its Graham Number of $7.65 — a significant margin of safety by Benjamin Graham's standard. The stock carries a low trailing P/E ratio of 5.2x.
On financial health, ABEO shows a moderate Piotroski F-Score of 5/9, and strong return on equity of 51.9% (sector average: -20.1%), and minimal leverage with a debt-to-equity ratio of 0.12.
StockPik's composite Value Score for ABEO is 100/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
ABEO reports a high gross margin of 73.7% (sector average: 37.4%) and a negative operating margin of -1,434.6%.
ABEO shows revenue growing at 66% year-over-year, with earnings growing at 212%.